Literature DB >> 22292447

Predictors of remission with placebo using an integrated study database from patients with major depressive disorder.

J C Nelson1, Q Zhang, W Deberdt, L B Marangell, O Karamustafalioglu, I A Lipkovich.   

Abstract

OBJECTIVE: To identify predictors of remission with placebo treatment in double-blind randomized controlled trials (RCTs) in major depressive disorder (MDD).
METHOD: A total of 1017 placebo-treated patients with baseline Hamilton Depression rating scale (HAMD) total ≥15 from eight duloxetine RCTs were included. Remission was defined as endpoint (7-8 weeks) HAMD total ≤7. Data were randomly split into training data (N = 813, 80%) for model selection and test data (N = 204, 20%) for validation. Logistic regression and classification and regression tree (CART) methods were used to identify predictors of remission. Predictive accuracy of models was assessed by Receiver Operator Characteristic (ROC) curves.
RESULTS: Baseline predictors for remission with placebo consistently identified with the logistic regression and CART analysis were less severe depressive symptoms (based on HAMD core symptoms), younger age, less anxiety (based on HAMD anxiety/somatization), and shorter current MDD episode duration. Associated cut-off values from the CART method characterized patient groups according to their remission likelihood. However, the predictive accuracy was modest for both methods with areas under the ROC curve of 0.6-0.65 based on test data.
CONCLUSION: The derived models, although of limited value for predicting remission in individual patients, may be useful for adjusting for placebo effects in clinical trials.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22292447     DOI: 10.1185/03007995.2011.654010

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  14 in total

1.  Combining moderators to identify clinical profiles of patients who will, and will not, benefit from aripiprazole augmentation for treatment resistant late-life major depressive disorder.

Authors:  Stephen F Smagula; Meredith L Wallace; Stewart J Anderson; Jordan F Karp; Eric J Lenze; Benoit H Mulsant; Meryl A Butters; Daniel M Blumberger; Breno S Diniz; Francis E Lotrich; Mary Amanda Dew; Charles F Reynolds
Journal:  J Psychiatr Res       Date:  2016-07-07       Impact factor: 4.791

2.  Bouncing back: remission from depression in a 12-year panel study of a representative Canadian community sample.

Authors:  Esme Fuller-Thomson; Marla Battiston; Tahany M Gadalla; Sarah Brennenstuhl
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2014-01-09       Impact factor: 4.328

3.  Examining raphe-amygdala structural connectivity as a biological predictor of SSRI response.

Authors:  Rajapillai L I Pillai; Chuan Huang; Andrew LaBella; Mengru Zhang; Jie Yang; Madhukar Trivedi; Myrna Weissman; Patrick McGrath; Maurizio Fava; Benji Kurian; Crystal Cooper; Melvin McInnis; Maria A Oquendo; Diego A Pizzagalli; Ramin V Parsey; Christine DeLorenzo
Journal:  J Affect Disord       Date:  2019-05-28       Impact factor: 4.839

4.  Dynamic prediction of treatment response in late-life depression.

Authors:  Ian Joel; Amy E Begley; Benoit H Mulsant; Eric J Lenze; Sati Mazumdar; Mary Amanda Dew; Daniel Blumberger; Meryl Butters; Charles F Reynolds
Journal:  Am J Geriatr Psychiatry       Date:  2013-02-06       Impact factor: 4.105

Review 5.  Using patient self-reports to study heterogeneity of treatment effects in major depressive disorder.

Authors:  R C Kessler; H M van Loo; K J Wardenaar; R M Bossarte; L A Brenner; D D Ebert; P de Jonge; A A Nierenberg; A J Rosellini; N A Sampson; R A Schoevers; M A Wilcox; A M Zaslavsky
Journal:  Epidemiol Psychiatr Sci       Date:  2016-01-26       Impact factor: 6.892

6.  A methylation study of long-term depression risk.

Authors:  Shaunna L Clark; Mohammad W Hattab; Robin F Chan; Andrey A Shabalin; Laura K M Han; Min Zhao; Johannes H Smit; Rick Jansen; Yuri Milaneschi; Lin Ying Xie; Gerard van Grootheest; Brenda W J H Penninx; Karolina A Aberg; Edwin J C G van den Oord
Journal:  Mol Psychiatry       Date:  2019-09-09       Impact factor: 15.992

Review 7.  Mechanisms of the placebo effect in pain and psychiatric disorders.

Authors:  R D Holmes; A K Tiwari; J L Kennedy
Journal:  Pharmacogenomics J       Date:  2016-03-22       Impact factor: 3.550

8.  The effects of co-morbidity in defining major depression subtypes associated with long-term course and severity.

Authors:  K J Wardenaar; H M van Loo; T Cai; M Fava; M J Gruber; J Li; P de Jonge; A A Nierenberg; M V Petukhova; S Rose; N A Sampson; R A Schoevers; M A Wilcox; J Alonso; E J Bromet; B Bunting; S E Florescu; A Fukao; O Gureje; C Hu; Y Q Huang; A N Karam; D Levinson; M E Medina Mora; J Posada-Villa; K M Scott; N I Taib; M C Viana; M Xavier; Z Zarkov; R C Kessler
Journal:  Psychol Med       Date:  2014-07-17       Impact factor: 7.723

9.  Major depressive disorder subtypes to predict long-term course.

Authors:  Hanna M van Loo; Tianxi Cai; Michael J Gruber; Junlong Li; Peter de Jonge; Maria Petukhova; Sherri Rose; Nancy A Sampson; Robert A Schoevers; Klaas J Wardenaar; Marsha A Wilcox; Ali Obaid Al-Hamzawi; Laura Helena Andrade; Evelyn J Bromet; Brendan Bunting; John Fayyad; Silvia E Florescu; Oye Gureje; Chiyi Hu; Yueqin Huang; Daphna Levinson; Maria Elena Medina-Mora; Yoshibumi Nakane; Jose Posada-Villa; Kate M Scott; Miguel Xavier; Zahari Zarkov; Ronald C Kessler
Journal:  Depress Anxiety       Date:  2014-01-14       Impact factor: 6.505

10.  Predictors of Remission in Acute and Continuation Treatment of Depressive Disorders.

Authors:  Ha-Yeon Kim; Hee-Joon Lee; Min Jhon; Ju-Wan Kim; Hee-Ju Kang; Ju-Yeon Lee; Sung-Wan Kim; Il-Seon Shin; Jae-Min Kim
Journal:  Clin Psychopharmacol Neurosci       Date:  2021-08-31       Impact factor: 2.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.